Simpson Thacher Loses Bid to Squash Investors' Class Claims over Pfizer Drug

, The Litigation Daily

   | 0 Comments

The antidepressant Pristiq may not have been the blockbuster investors hoped for, but it could turn out to be a serious moneymaker for plaintiffs lawyers at Robbins Geller Rudman & Dowd.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202571827619

Thank you!

This article's comments will be reviewed.